| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 249 | 2015 | 2636 | 8.070 |
Why?
|
| Receptors, Estrogen | 114 | 2015 | 727 | 5.200 |
Why?
|
| Tamoxifen | 74 | 2011 | 349 | 4.760 |
Why?
|
| Antineoplastic Agents, Hormonal | 48 | 2011 | 256 | 4.260 |
Why?
|
| Poaceae | 9 | 2025 | 15 | 2.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 48 | 2015 | 1348 | 1.960 |
Why?
|
| Receptors, Progesterone | 46 | 2012 | 683 | 1.880 |
Why?
|
| Estrogen Antagonists | 23 | 2011 | 93 | 1.640 |
Why?
|
| Drug Resistance, Neoplasm | 24 | 2011 | 819 | 1.430 |
Why?
|
| Neoplasms, Hormone-Dependent | 19 | 2011 | 92 | 1.400 |
Why?
|
| Biomarkers, Tumor | 30 | 2013 | 1616 | 1.330 |
Why?
|
| Photosynthesis | 5 | 2025 | 12 | 1.290 |
Why?
|
| Estradiol | 22 | 2010 | 483 | 1.220 |
Why?
|
| Antineoplastic Agents | 25 | 2015 | 1802 | 1.030 |
Why?
|
| Quinazolines | 7 | 2015 | 181 | 0.960 |
Why?
|
| Estrogen Receptor Modulators | 10 | 2005 | 39 | 0.840 |
Why?
|
| Plant Leaves | 5 | 2025 | 55 | 0.780 |
Why?
|
| DNA, Neoplasm | 18 | 2013 | 286 | 0.780 |
Why?
|
| Aromatase Inhibitors | 10 | 2015 | 78 | 0.760 |
Why?
|
| Selective Estrogen Receptor Modulators | 7 | 2010 | 52 | 0.760 |
Why?
|
| Water | 3 | 2025 | 188 | 0.750 |
Why?
|
| Growth Substances | 9 | 2004 | 102 | 0.730 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2015 | 569 | 0.730 |
Why?
|
| Cyclophosphamide | 34 | 2011 | 438 | 0.690 |
Why?
|
| Female | 215 | 2015 | 70755 | 0.680 |
Why?
|
| ErbB Receptors | 16 | 2011 | 294 | 0.660 |
Why?
|
| Chemotherapy, Adjuvant | 25 | 2010 | 389 | 0.640 |
Why?
|
| Estrogens | 19 | 2006 | 436 | 0.630 |
Why?
|
| Gene Expression Regulation, Neoplastic | 22 | 2009 | 1975 | 0.620 |
Why?
|
| Neoplasm Metastasis | 22 | 2015 | 703 | 0.610 |
Why?
|
| Nitriles | 8 | 2015 | 164 | 0.580 |
Why?
|
| Lymphatic Metastasis | 34 | 2009 | 431 | 0.580 |
Why?
|
| Cell Division | 35 | 2003 | 723 | 0.570 |
Why?
|
| Humans | 265 | 2015 | 130931 | 0.570 |
Why?
|
| Doxorubicin | 22 | 2011 | 298 | 0.570 |
Why?
|
| Tumor Cells, Cultured | 28 | 2003 | 989 | 0.550 |
Why?
|
| Fluorouracil | 29 | 2010 | 134 | 0.530 |
Why?
|
| Receptor Cross-Talk | 5 | 2011 | 36 | 0.520 |
Why?
|
| Gene Transfer, Horizontal | 2 | 2019 | 45 | 0.520 |
Why?
|
| Disease-Free Survival | 30 | 2010 | 910 | 0.520 |
Why?
|
| Carcinoma | 4 | 2015 | 283 | 0.520 |
Why?
|
| Triazoles | 8 | 2015 | 144 | 0.490 |
Why?
|
| Receptors, Growth Factor | 3 | 2005 | 35 | 0.490 |
Why?
|
| Carbon Dioxide | 2 | 2014 | 276 | 0.470 |
Why?
|
| Prognosis | 59 | 2015 | 4930 | 0.470 |
Why?
|
| Droughts | 2 | 2021 | 12 | 0.470 |
Why?
|
| Plant Proteins | 2 | 2013 | 83 | 0.460 |
Why?
|
| Genes, Plant | 2 | 2019 | 38 | 0.430 |
Why?
|
| Evolution, Molecular | 3 | 2019 | 656 | 0.410 |
Why?
|
| Mice, Nude | 24 | 2008 | 715 | 0.410 |
Why?
|
| Mucin-1 | 1 | 2013 | 34 | 0.390 |
Why?
|
| Signal Transduction | 21 | 2011 | 4645 | 0.390 |
Why?
|
| Insulin-Like Growth Factor I | 10 | 2006 | 324 | 0.390 |
Why?
|
| Estrogen Receptor alpha | 6 | 2008 | 433 | 0.370 |
Why?
|
| Clinical Trials as Topic | 16 | 2011 | 1134 | 0.360 |
Why?
|
| Drug Resistance | 14 | 2005 | 249 | 0.360 |
Why?
|
| Immunohistochemistry | 16 | 2010 | 1614 | 0.360 |
Why?
|
| Middle Aged | 85 | 2011 | 28735 | 0.350 |
Why?
|
| Aged | 67 | 2011 | 21134 | 0.350 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2011 | 63 | 0.350 |
Why?
|
| Plants | 2 | 2021 | 45 | 0.340 |
Why?
|
| Survival Analysis | 23 | 2007 | 1523 | 0.330 |
Why?
|
| Lymph Nodes | 15 | 2009 | 375 | 0.330 |
Why?
|
| Receptors, Cell Surface | 11 | 1995 | 428 | 0.330 |
Why?
|
| Adenocarcinoma | 9 | 2009 | 991 | 0.330 |
Why?
|
| Gene Expression Profiling | 8 | 2015 | 1821 | 0.320 |
Why?
|
| Methotrexate | 23 | 2010 | 342 | 0.320 |
Why?
|
| Sirolimus | 1 | 2012 | 231 | 0.320 |
Why?
|
| Prednisone | 17 | 2011 | 244 | 0.320 |
Why?
|
| Lymphoma | 4 | 2011 | 327 | 0.310 |
Why?
|
| Repressor Proteins | 6 | 2005 | 778 | 0.310 |
Why?
|
| Heat-Shock Proteins | 5 | 2011 | 179 | 0.300 |
Why?
|
| Climate Change | 3 | 2021 | 61 | 0.300 |
Why?
|
| Biological Evolution | 4 | 2023 | 229 | 0.300 |
Why?
|
| Trees | 2 | 2019 | 20 | 0.290 |
Why?
|
| Ovariectomy | 5 | 1998 | 166 | 0.290 |
Why?
|
| Adult | 71 | 2011 | 31541 | 0.290 |
Why?
|
| Proportional Hazards Models | 13 | 2009 | 1401 | 0.280 |
Why?
|
| Vincristine | 12 | 2011 | 194 | 0.280 |
Why?
|
| Transcription Factors | 6 | 2003 | 2430 | 0.270 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 671 | 0.270 |
Why?
|
| Nuclear Proteins | 7 | 2005 | 1227 | 0.270 |
Why?
|
| Somatomedins | 4 | 1999 | 33 | 0.270 |
Why?
|
| Aged, 80 and over | 24 | 2011 | 6862 | 0.260 |
Why?
|
| Postmenopause | 11 | 2009 | 149 | 0.250 |
Why?
|
| Antibiotics, Antineoplastic | 5 | 2009 | 124 | 0.240 |
Why?
|
| Ploidies | 10 | 2000 | 35 | 0.240 |
Why?
|
| Genes, erbB-1 | 1 | 2005 | 9 | 0.230 |
Why?
|
| Trastuzumab | 4 | 2015 | 148 | 0.230 |
Why?
|
| Enzyme Inhibitors | 5 | 2004 | 565 | 0.220 |
Why?
|
| Animals | 55 | 2018 | 34278 | 0.220 |
Why?
|
| Epidermal Growth Factor | 6 | 2004 | 116 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2003 | 189 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 10 | 2011 | 1006 | 0.210 |
Why?
|
| Transcription Factor AP-1 | 2 | 2002 | 113 | 0.210 |
Why?
|
| Receptors, Retinoic Acid | 2 | 2003 | 76 | 0.210 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 1999 | 237 | 0.210 |
Why?
|
| Goserelin | 3 | 2005 | 4 | 0.200 |
Why?
|
| Cell Line | 22 | 2003 | 2596 | 0.200 |
Why?
|
| Combined Modality Therapy | 17 | 2005 | 1249 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 1 | 2005 | 143 | 0.200 |
Why?
|
| Neoplasm Proteins | 8 | 2000 | 674 | 0.200 |
Why?
|
| Adaptation, Physiological | 1 | 2025 | 261 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 1998 | 172 | 0.200 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2005 | 102 | 0.200 |
Why?
|
| Prostatic Neoplasms | 5 | 1992 | 1412 | 0.190 |
Why?
|
| Treatment Outcome | 28 | 2011 | 12858 | 0.190 |
Why?
|
| Computer Simulation | 1 | 2006 | 686 | 0.190 |
Why?
|
| Ecosystem | 2 | 2020 | 100 | 0.190 |
Why?
|
| Drug Administration Schedule | 12 | 2007 | 741 | 0.190 |
Why?
|
| Insulin-Like Growth Factor II | 3 | 1992 | 38 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 1998 | 738 | 0.180 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2010 | 87 | 0.180 |
Why?
|
| Mice | 36 | 2015 | 18410 | 0.180 |
Why?
|
| Genetic Markers | 1 | 2003 | 605 | 0.180 |
Why?
|
| Transforming Growth Factor alpha | 4 | 1994 | 26 | 0.180 |
Why?
|
| Phylogeny | 4 | 2020 | 706 | 0.170 |
Why?
|
| Xylem | 1 | 2021 | 3 | 0.170 |
Why?
|
| Survival Rate | 15 | 2005 | 2138 | 0.170 |
Why?
|
| Acclimatization | 1 | 2021 | 21 | 0.170 |
Why?
|
| Trans-Activators | 3 | 2005 | 690 | 0.170 |
Why?
|
| Transforming Growth Factors | 5 | 1988 | 18 | 0.170 |
Why?
|
| Phenotype | 7 | 2021 | 4493 | 0.170 |
Why?
|
| Transfection | 9 | 2002 | 960 | 0.170 |
Why?
|
| Predictive Value of Tests | 14 | 2010 | 2287 | 0.170 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 1998 | 72 | 0.160 |
Why?
|
| Plant Stomata | 2 | 2025 | 7 | 0.160 |
Why?
|
| Taxoids | 3 | 2005 | 71 | 0.160 |
Why?
|
| Neoplasms, Experimental | 6 | 1989 | 206 | 0.160 |
Why?
|
| Genes, erbB-2 | 3 | 2011 | 32 | 0.160 |
Why?
|
| Cell Proliferation | 6 | 2011 | 2459 | 0.160 |
Why?
|
| Polymorphism, Genetic | 4 | 2010 | 794 | 0.160 |
Why?
|
| Melphalan | 4 | 2003 | 44 | 0.150 |
Why?
|
| Mitoxantrone | 7 | 1999 | 29 | 0.150 |
Why?
|
| Neoplasm Transplantation | 9 | 2006 | 363 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2021 | 1220 | 0.150 |
Why?
|
| Mesoderm | 1 | 2009 | 107 | 0.150 |
Why?
|
| Domestication | 1 | 2018 | 4 | 0.150 |
Why?
|
| Soil | 1 | 2019 | 76 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 2 | 2011 | 383 | 0.150 |
Why?
|
| Crops, Agricultural | 1 | 2018 | 15 | 0.150 |
Why?
|
| Animals, Domestic | 1 | 2018 | 37 | 0.150 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 137 | 0.150 |
Why?
|
| Peptides | 5 | 1988 | 835 | 0.140 |
Why?
|
| Nuclear Matrix-Associated Proteins | 3 | 2005 | 19 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2000 | 690 | 0.140 |
Why?
|
| Matrix Attachment Region Binding Proteins | 3 | 2005 | 19 | 0.140 |
Why?
|
| Carbon | 2 | 2019 | 94 | 0.140 |
Why?
|
| S Phase | 8 | 2000 | 73 | 0.140 |
Why?
|
| Forests | 1 | 2017 | 14 | 0.140 |
Why?
|
| Menopause | 10 | 2003 | 87 | 0.140 |
Why?
|
| Disease Progression | 11 | 2011 | 2191 | 0.140 |
Why?
|
| Multivariate Analysis | 7 | 2004 | 1395 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2007 | 1625 | 0.130 |
Why?
|
| Anticarcinogenic Agents | 2 | 2010 | 46 | 0.130 |
Why?
|
| Time Factors | 18 | 2010 | 6275 | 0.130 |
Why?
|
| Tetrahydronaphthalenes | 2 | 2010 | 30 | 0.130 |
Why?
|
| Double-Blind Method | 7 | 2010 | 1633 | 0.130 |
Why?
|
| Transcriptome | 3 | 2015 | 1144 | 0.130 |
Why?
|
| Transplantation, Heterologous | 8 | 2006 | 261 | 0.130 |
Why?
|
| Cathepsin D | 2 | 1994 | 16 | 0.130 |
Why?
|
| Drug Evaluation | 8 | 1992 | 102 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 6 | 2010 | 644 | 0.130 |
Why?
|
| Flow Cytometry | 9 | 1999 | 768 | 0.130 |
Why?
|
| Receptors, Steroid | 4 | 1992 | 172 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 4 | 1994 | 598 | 0.120 |
Why?
|
| Loss of Heterozygosity | 3 | 2001 | 124 | 0.120 |
Why?
|
| Axilla | 10 | 2005 | 43 | 0.120 |
Why?
|
| Blotting, Western | 5 | 2003 | 1018 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2011 | 224 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2000 | 798 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2010 | 1270 | 0.120 |
Why?
|
| Phosphorylation | 9 | 2008 | 1565 | 0.120 |
Why?
|
| Hormones | 5 | 1989 | 165 | 0.120 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 172 | 0.120 |
Why?
|
| Hematopoietic Cell Growth Factors | 2 | 1991 | 9 | 0.110 |
Why?
|
| Receptors, Somatomedin | 6 | 1999 | 21 | 0.110 |
Why?
|
| Megestrol | 2 | 1997 | 2 | 0.110 |
Why?
|
| Models, Biological | 5 | 2025 | 1389 | 0.110 |
Why?
|
| Neutropenia | 2 | 2010 | 205 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 4 | 2009 | 1490 | 0.110 |
Why?
|
| Insulin | 7 | 1984 | 1148 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 78 | 0.110 |
Why?
|
| Kinetics | 10 | 1990 | 1101 | 0.110 |
Why?
|
| Immunotoxins | 1 | 1994 | 21 | 0.110 |
Why?
|
| South Africa | 1 | 2014 | 105 | 0.100 |
Why?
|
| Nursing Assessment | 1 | 1993 | 25 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1994 | 70 | 0.100 |
Why?
|
| Gene Expression | 5 | 2002 | 1500 | 0.100 |
Why?
|
| Premenopause | 5 | 2005 | 38 | 0.100 |
Why?
|
| Orientation | 1 | 1993 | 39 | 0.100 |
Why?
|
| Mastectomy | 7 | 2005 | 75 | 0.100 |
Why?
|
| Gene Amplification | 3 | 2011 | 228 | 0.100 |
Why?
|
| Analysis of Variance | 6 | 1997 | 955 | 0.100 |
Why?
|
| Phosphoproteins | 3 | 2001 | 435 | 0.100 |
Why?
|
| Logistic Models | 5 | 2010 | 1822 | 0.100 |
Why?
|
| Air | 1 | 2013 | 23 | 0.100 |
Why?
|
| Histone Deacetylases | 2 | 2005 | 119 | 0.100 |
Why?
|
| Pyrrolidines | 2 | 2010 | 47 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 4 | 2011 | 92 | 0.100 |
Why?
|
| Vinblastine | 2 | 2011 | 55 | 0.100 |
Why?
|
| Tyrphostins | 1 | 1992 | 13 | 0.100 |
Why?
|
| Histone Acetyltransferases | 2 | 2003 | 224 | 0.100 |
Why?
|
| Data Collection | 2 | 1993 | 372 | 0.090 |
Why?
|
| Nurses | 1 | 1993 | 80 | 0.090 |
Why?
|
| Cell Line, Tumor | 9 | 2015 | 3642 | 0.090 |
Why?
|
| Research Personnel | 1 | 1993 | 136 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 7 | 2004 | 1018 | 0.090 |
Why?
|
| Phosphotransferases | 1 | 1992 | 33 | 0.090 |
Why?
|
| Sequence Analysis, Protein | 1 | 2012 | 48 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 5 | 2006 | 1217 | 0.090 |
Why?
|
| Plasmids | 2 | 2002 | 455 | 0.090 |
Why?
|
| Everolimus | 1 | 2012 | 48 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 61 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2001 | 198 | 0.090 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1992 | 79 | 0.090 |
Why?
|
| Bleomycin | 1 | 2011 | 111 | 0.090 |
Why?
|
| Dacarbazine | 1 | 2011 | 92 | 0.090 |
Why?
|
| Genetic Vectors | 2 | 1994 | 900 | 0.090 |
Why?
|
| Nuclear Receptor Coactivator 3 | 2 | 2003 | 257 | 0.090 |
Why?
|
| Molecular Sequence Data | 5 | 2012 | 3610 | 0.090 |
Why?
|
| Forecasting | 3 | 2005 | 364 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2010 | 98 | 0.090 |
Why?
|
| Activities of Daily Living | 1 | 1993 | 409 | 0.090 |
Why?
|
| Motivation | 1 | 1993 | 334 | 0.080 |
Why?
|
| Fertility Preservation | 1 | 2011 | 63 | 0.080 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2010 | 31 | 0.080 |
Why?
|
| Women's Health | 1 | 2012 | 143 | 0.080 |
Why?
|
| Pyridines | 1 | 1992 | 258 | 0.080 |
Why?
|
| Follow-Up Studies | 10 | 2007 | 5257 | 0.080 |
Why?
|
| Paclitaxel | 2 | 2003 | 134 | 0.080 |
Why?
|
| Cell Cycle | 7 | 2006 | 600 | 0.080 |
Why?
|
| Sequence Alignment | 1 | 2012 | 593 | 0.080 |
Why?
|
| Rituximab | 1 | 2011 | 172 | 0.080 |
Why?
|
| Quality of Life | 4 | 2002 | 2096 | 0.080 |
Why?
|
| Placebos | 1 | 2011 | 227 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 33 | 0.080 |
Why?
|
| Southwestern United States | 3 | 2010 | 44 | 0.080 |
Why?
|
| Amino Acid Sequence | 3 | 2012 | 2560 | 0.080 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2010 | 193 | 0.080 |
Why?
|
| Peroxidase | 1 | 2009 | 62 | 0.080 |
Why?
|
| Transcription, Genetic | 3 | 2008 | 1396 | 0.080 |
Why?
|
| Acronine | 1 | 1989 | 1 | 0.080 |
Why?
|
| Biopsy, Needle | 5 | 2005 | 216 | 0.070 |
Why?
|
| Treatment Failure | 4 | 2010 | 350 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1991 | 646 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 200 | 0.070 |
Why?
|
| Alkaloids | 1 | 1989 | 36 | 0.070 |
Why?
|
| Apoptosis | 4 | 2005 | 1852 | 0.070 |
Why?
|
| Ki-67 Antigen | 3 | 2000 | 104 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2009 | 188 | 0.070 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 3 | 2005 | 51 | 0.070 |
Why?
|
| DNA | 4 | 2006 | 1444 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2010 | 200 | 0.070 |
Why?
|
| Pregnancy Outcome | 1 | 2011 | 630 | 0.070 |
Why?
|
| Disease Models, Animal | 6 | 2015 | 4681 | 0.070 |
Why?
|
| DNA-Binding Proteins | 4 | 2000 | 1951 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 1994 | 111 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 266 | 0.070 |
Why?
|
| Biopsy | 7 | 2009 | 1248 | 0.070 |
Why?
|
| Transcriptional Activation | 2 | 2000 | 415 | 0.070 |
Why?
|
| Cell Nucleus | 5 | 2000 | 564 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 1994 | 334 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 1989 | 191 | 0.070 |
Why?
|
| Binding, Competitive | 3 | 2000 | 153 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 1993 | 710 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 6 | 2006 | 397 | 0.070 |
Why?
|
| Anthraquinones | 2 | 1985 | 9 | 0.070 |
Why?
|
| United States | 12 | 2010 | 11718 | 0.070 |
Why?
|
| Estrogen Receptor beta | 2 | 2004 | 81 | 0.070 |
Why?
|
| North America | 2 | 2010 | 256 | 0.070 |
Why?
|
| Protein Binding | 5 | 2004 | 1705 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 606 | 0.060 |
Why?
|
| Receptors, Interleukin | 1 | 2006 | 37 | 0.060 |
Why?
|
| Pain Management | 1 | 1989 | 198 | 0.060 |
Why?
|
| Ligands | 4 | 2004 | 485 | 0.060 |
Why?
|
| Cytosol | 3 | 1997 | 139 | 0.060 |
Why?
|
| Receptors, Somatotropin | 1 | 2006 | 9 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2008 | 1009 | 0.060 |
Why?
|
| Benzamides | 1 | 2006 | 122 | 0.060 |
Why?
|
| Glutathione Transferase | 2 | 2010 | 145 | 0.060 |
Why?
|
| Medroxyprogesterone | 2 | 1985 | 9 | 0.060 |
Why?
|
| Anthracenes | 6 | 1991 | 9 | 0.060 |
Why?
|
| Neoplasms | 6 | 2012 | 2955 | 0.060 |
Why?
|
| Human Growth Hormone | 1 | 2006 | 75 | 0.060 |
Why?
|
| Decision Making | 2 | 2003 | 680 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2012 | 893 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 1990 | 1021 | 0.060 |
Why?
|
| Neoplasm Staging | 6 | 2007 | 1315 | 0.060 |
Why?
|
| Plant Transpiration | 1 | 2025 | 3 | 0.060 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1985 | 34 | 0.060 |
Why?
|
| Colony-Forming Units Assay | 1 | 1985 | 63 | 0.060 |
Why?
|
| Mastectomy, Radical | 3 | 2003 | 9 | 0.060 |
Why?
|
| RNA, Messenger | 5 | 2002 | 2575 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2010 | 6443 | 0.060 |
Why?
|
| Drug Approval | 1 | 2005 | 44 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 123 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 1997 | 33 | 0.050 |
Why?
|
| Proteinuria | 1 | 2005 | 106 | 0.050 |
Why?
|
| Dog Diseases | 1 | 2005 | 58 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2002 | 85 | 0.050 |
Why?
|
| RNA, Neoplasm | 4 | 1990 | 127 | 0.050 |
Why?
|
| In Situ Hybridization | 2 | 1995 | 451 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2004 | 186 | 0.050 |
Why?
|
| Cell Size | 1 | 2023 | 81 | 0.050 |
Why?
|
| Androstenedione | 1 | 2003 | 15 | 0.050 |
Why?
|
| Metallothionein | 2 | 1994 | 16 | 0.050 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2003 | 162 | 0.050 |
Why?
|
| Algorithms | 4 | 2010 | 1680 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2006 | 566 | 0.050 |
Why?
|
| Acetyltransferases | 1 | 2003 | 72 | 0.050 |
Why?
|
| Oncogene Proteins, Viral | 2 | 1994 | 62 | 0.050 |
Why?
|
| Creatinine | 1 | 2005 | 402 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2009 | 76 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2009 | 1094 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2001 | 96 | 0.050 |
Why?
|
| Bone Density | 2 | 2010 | 360 | 0.050 |
Why?
|
| Breast | 4 | 2003 | 215 | 0.050 |
Why?
|
| Proteins | 2 | 2001 | 1025 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2003 | 251 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2007 | 549 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 134 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 1983 | 163 | 0.050 |
Why?
|
| Cisplatin | 4 | 2009 | 284 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2000 | 578 | 0.050 |
Why?
|
| Statistics as Topic | 3 | 1999 | 243 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2004 | 237 | 0.050 |
Why?
|
| Research | 3 | 1995 | 266 | 0.050 |
Why?
|
| Retrospective Studies | 10 | 2009 | 17485 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2004 | 703 | 0.050 |
Why?
|
| Plant Physiological Phenomena | 1 | 2021 | 7 | 0.050 |
Why?
|
| Mastectomy, Segmental | 2 | 2004 | 39 | 0.050 |
Why?
|
| Hyperbaric Oxygenation | 2 | 1973 | 20 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2003 | 177 | 0.040 |
Why?
|
| Stereoisomerism | 2 | 1992 | 116 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2010 | 1233 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2009 | 1248 | 0.040 |
Why?
|
| BRCA1 Protein | 2 | 1999 | 82 | 0.040 |
Why?
|
| Phorbols | 1 | 1981 | 5 | 0.040 |
Why?
|
| Radioimmunoassay | 2 | 1991 | 99 | 0.040 |
Why?
|
| Nucleoside-Diphosphate Kinase | 1 | 2001 | 4 | 0.040 |
Why?
|
| Climate | 1 | 2021 | 26 | 0.040 |
Why?
|
| Biophysical Phenomena | 1 | 2021 | 39 | 0.040 |
Why?
|
| Australia | 1 | 2021 | 173 | 0.040 |
Why?
|
| Phorbol Esters | 1 | 1981 | 21 | 0.040 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2001 | 28 | 0.040 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2000 | 59 | 0.040 |
Why?
|
| Azacitidine | 1 | 2001 | 51 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2001 | 59 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2002 | 272 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2000 | 35 | 0.040 |
Why?
|
| Cold Temperature | 1 | 2021 | 82 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2000 | 44 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2003 | 402 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2008 | 484 | 0.040 |
Why?
|
| Plant Dispersal | 1 | 2020 | 1 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2000 | 90 | 0.040 |
Why?
|
| Glucocorticoids | 3 | 1979 | 350 | 0.040 |
Why?
|
| Risk Factors | 10 | 2010 | 10901 | 0.040 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 1997 | 34 | 0.040 |
Why?
|
| Carbon Sequestration | 1 | 2019 | 6 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2010 | 3675 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2000 | 142 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 1235 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 1997 | 50 | 0.040 |
Why?
|
| Claudin-1 | 1 | 2009 | 19 | 0.040 |
Why?
|
| Insulin Antagonists | 1 | 1979 | 4 | 0.040 |
Why?
|
| Protein Kinases | 2 | 2008 | 321 | 0.040 |
Why?
|
| CD24 Antigen | 1 | 2009 | 31 | 0.040 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2019 | 62 | 0.040 |
Why?
|
| Molecular Weight | 2 | 1990 | 298 | 0.040 |
Why?
|
| Genome | 2 | 2019 | 472 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 2009 | 247 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2009 | 65 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2008 | 439 | 0.040 |
Why?
|
| Pregnancy | 2 | 2011 | 7558 | 0.040 |
Why?
|
| Patient Selection | 3 | 2009 | 724 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 1998 | 17 | 0.040 |
Why?
|
| Cyclins | 1 | 1999 | 94 | 0.040 |
Why?
|
| Depression, Chemical | 2 | 2000 | 35 | 0.040 |
Why?
|
| Down-Regulation | 3 | 2005 | 660 | 0.040 |
Why?
|
| Epithelium | 1 | 2009 | 343 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2009 | 187 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 2 | 1989 | 66 | 0.030 |
Why?
|
| Hormone Antagonists | 1 | 1998 | 45 | 0.030 |
Why?
|
| Medical Oncology | 2 | 2010 | 237 | 0.030 |
Why?
|
| Aminoglutethimide | 1 | 1997 | 3 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2004 | 291 | 0.030 |
Why?
|
| Mammography | 2 | 2010 | 130 | 0.030 |
Why?
|
| DNA Replication | 2 | 1989 | 358 | 0.030 |
Why?
|
| Centrifugation | 1 | 1997 | 23 | 0.030 |
Why?
|
| Cell Survival | 3 | 1989 | 850 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 1998 | 111 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 1997 | 20 | 0.030 |
Why?
|
| Cell Movement | 1 | 2001 | 874 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1991 | 1311 | 0.030 |
Why?
|
| Lung Neoplasms | 4 | 2015 | 1527 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2009 | 463 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2008 | 237 | 0.030 |
Why?
|
| Telomerase | 1 | 1997 | 157 | 0.030 |
Why?
|
| Nucleic Acids | 2 | 2012 | 26 | 0.030 |
Why?
|
| DNA Primers | 4 | 1999 | 609 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 939 | 0.030 |
Why?
|
| Age Factors | 3 | 2007 | 2866 | 0.030 |
Why?
|
| Thymidine | 3 | 1982 | 52 | 0.030 |
Why?
|
| Receptor, Insulin | 5 | 1999 | 66 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1997 | 223 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 345 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 1997 | 205 | 0.030 |
Why?
|
| Testosterone | 1 | 1982 | 603 | 0.030 |
Why?
|
| Cytoplasm | 2 | 1995 | 252 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 1997 | 245 | 0.030 |
Why?
|
| Societies, Medical | 2 | 2010 | 788 | 0.030 |
Why?
|
| DNA Damage | 1 | 1999 | 523 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2008 | 428 | 0.030 |
Why?
|
| Male | 15 | 2005 | 64823 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 1996 | 126 | 0.030 |
Why?
|
| Interphase | 2 | 1987 | 35 | 0.030 |
Why?
|
| Leukopenia | 3 | 1985 | 45 | 0.030 |
Why?
|
| Hyperplasia | 3 | 2005 | 185 | 0.030 |
Why?
|
| Mutation | 4 | 2003 | 6144 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1998 | 649 | 0.030 |
Why?
|
| Remission Induction | 2 | 1998 | 306 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 1994 | 83 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 1998 | 611 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2003 | 1256 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1996 | 567 | 0.030 |
Why?
|
| Clone Cells | 3 | 1985 | 170 | 0.030 |
Why?
|
| Palliative Care | 1 | 1998 | 442 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2001 | 1082 | 0.030 |
Why?
|
| Bone Neoplasms | 3 | 2000 | 441 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 194 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1994 | 43 | 0.030 |
Why?
|
| Isomerism | 1 | 1994 | 25 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1994 | 188 | 0.030 |
Why?
|
| Hematologic Tests | 1 | 1994 | 37 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 1993 | 785 | 0.030 |
Why?
|
| Castration | 3 | 1985 | 31 | 0.030 |
Why?
|
| Rats | 6 | 2000 | 3457 | 0.030 |
Why?
|
| Quality Control | 1 | 1993 | 118 | 0.030 |
Why?
|
| Vitamin E Deficiency | 1 | 1973 | 2 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1996 | 579 | 0.020 |
Why?
|
| Peroxides | 1 | 1973 | 7 | 0.020 |
Why?
|
| Dexamethasone | 3 | 1980 | 258 | 0.020 |
Why?
|
| Base Sequence | 4 | 2000 | 2781 | 0.020 |
Why?
|
| Methemoglobinemia | 1 | 1973 | 9 | 0.020 |
Why?
|
| Recurrence | 3 | 2009 | 1473 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1995 | 577 | 0.020 |
Why?
|
| Hemolysis | 1 | 1973 | 104 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2005 | 829 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2008 | 999 | 0.020 |
Why?
|
| Erythrocytes | 1 | 1973 | 190 | 0.020 |
Why?
|
| RNA Stability | 1 | 2012 | 75 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 1992 | 72 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1992 | 69 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2009 | 1611 | 0.020 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1991 | 4 | 0.020 |
Why?
|
| Gene Expression Regulation | 3 | 1998 | 2344 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1991 | 40 | 0.020 |
Why?
|
| Templates, Genetic | 1 | 1991 | 54 | 0.020 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2010 | 9 | 0.020 |
Why?
|
| Burnout, Professional | 1 | 1993 | 129 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Inactivation, Metabolic | 1 | 2010 | 26 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2010 | 25 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2010 | 40 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 109 | 0.020 |
Why?
|
| Diethylstilbestrol | 1 | 1990 | 42 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2010 | 49 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2010 | 50 | 0.020 |
Why?
|
| Orchiectomy | 1 | 1990 | 53 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 88 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2010 | 57 | 0.020 |
Why?
|
| Alanine | 1 | 1991 | 162 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2001 | 74 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2010 | 142 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2006 | 5096 | 0.020 |
Why?
|
| Uridine | 2 | 1980 | 31 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 2011 | 190 | 0.020 |
Why?
|
| Research Design | 2 | 2005 | 722 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 1973 | 373 | 0.020 |
Why?
|
| Karyotyping | 2 | 1987 | 314 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2010 | 174 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 2122 | 0.020 |
Why?
|
| Patient Care Team | 1 | 1993 | 558 | 0.020 |
Why?
|
| Buserelin | 1 | 1989 | 1 | 0.020 |
Why?
|
| Microfilament Proteins | 2 | 2003 | 272 | 0.020 |
Why?
|
| Cells, Cultured | 7 | 1987 | 2965 | 0.020 |
Why?
|
| Oncogenes | 1 | 1989 | 164 | 0.020 |
Why?
|
| Pilot Projects | 3 | 1999 | 1441 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 1989 | 307 | 0.020 |
Why?
|
| Solubility | 1 | 1989 | 120 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1992 | 464 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1991 | 594 | 0.020 |
Why?
|
| Affinity Labels | 1 | 1988 | 10 | 0.020 |
Why?
|
| Biological Availability | 1 | 1989 | 139 | 0.020 |
Why?
|
| Linear Models | 1 | 1990 | 694 | 0.020 |
Why?
|
| Adolescent | 3 | 2005 | 20814 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2010 | 749 | 0.020 |
Why?
|
| CHO Cells | 2 | 2000 | 149 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 2000 | 120 | 0.020 |
Why?
|
| Cricetinae | 2 | 2000 | 367 | 0.020 |
Why?
|
| Culture Techniques | 2 | 1978 | 75 | 0.020 |
Why?
|
| Fatty Acids | 3 | 1983 | 361 | 0.020 |
Why?
|
| Nausea | 2 | 1985 | 83 | 0.020 |
Why?
|
| Agar | 1 | 1987 | 17 | 0.020 |
Why?
|
| Biological Products | 1 | 1989 | 144 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1987 | 315 | 0.020 |
Why?
|
| Choline Dehydrogenase | 1 | 2006 | 2 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 1997 | 365 | 0.020 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2006 | 7 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1068 | 0.020 |
Why?
|
| Adrenalectomy | 3 | 1978 | 40 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 1987 | 132 | 0.020 |
Why?
|
| Culture Media | 2 | 1984 | 174 | 0.020 |
Why?
|
| Mitosis | 1 | 1987 | 190 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 1987 | 119 | 0.020 |
Why?
|
| Response Elements | 1 | 2006 | 99 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 310 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 642 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1989 | 399 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 429 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1985 | 8 | 0.010 |
Why?
|
| Liver Neoplasms | 3 | 2003 | 1383 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2005 | 55 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2009 | 275 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2005 | 51 | 0.010 |
Why?
|
| Phenylalanine | 1 | 1986 | 125 | 0.010 |
Why?
|
| Random Allocation | 4 | 1989 | 421 | 0.010 |
Why?
|
| Mammary Glands, Human | 1 | 2006 | 81 | 0.010 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2005 | 232 | 0.010 |
Why?
|
| Raloxifene Hydrochloride | 1 | 1985 | 16 | 0.010 |
Why?
|
| Risk | 2 | 1998 | 738 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 271 | 0.010 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1985 | 21 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2005 | 61 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1984 | 152 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1984 | 157 | 0.010 |
Why?
|
| Nafoxidine | 1 | 1984 | 4 | 0.010 |
Why?
|
| Phlebitis | 1 | 1984 | 1 | 0.010 |
Why?
|
| Chickens | 1 | 1984 | 285 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1984 | 126 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2004 | 120 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2005 | 123 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 1200 | 0.010 |
Why?
|
| Dogs | 1 | 2005 | 623 | 0.010 |
Why?
|
| Rabbits | 1 | 1984 | 632 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 1989 | 468 | 0.010 |
Why?
|
| Leydig Cell Tumor | 1 | 1983 | 7 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 1983 | 42 | 0.010 |
Why?
|
| Species Specificity | 1 | 1984 | 519 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 413 | 0.010 |
Why?
|
| Megestrol Acetate | 1 | 2003 | 2 | 0.010 |
Why?
|
| Thiotepa | 1 | 2003 | 18 | 0.010 |
Why?
|
| Editorial Policies | 1 | 2004 | 49 | 0.010 |
Why?
|
| Bone Resorption | 1 | 1983 | 52 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2005 | 666 | 0.010 |
Why?
|
| Toremifene | 1 | 2003 | 1 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2950 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 2651 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2010 | 3433 | 0.010 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2003 | 7 | 0.010 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (NADP+)(Phosphorylating) | 1 | 2002 | 1 | 0.010 |
Why?
|
| Piperidines | 1 | 1985 | 230 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 23 | 0.010 |
Why?
|
| Genes, Neoplasm | 1 | 2003 | 80 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 201 | 0.010 |
Why?
|
| Incidence | 1 | 2010 | 3327 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2003 | 272 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 755 | 0.010 |
Why?
|
| Progesterone | 1 | 1985 | 448 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2003 | 56 | 0.010 |
Why?
|
| Cause of Death | 1 | 2005 | 507 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1985 | 330 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 402 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1989 | 1941 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1983 | 224 | 0.010 |
Why?
|
| Acetates | 2 | 1979 | 83 | 0.010 |
Why?
|
| Spinal Cord Compression | 1 | 1982 | 31 | 0.010 |
Why?
|
| Hemagglutinins | 1 | 2001 | 25 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 3067 | 0.010 |
Why?
|
| Anaphylaxis | 1 | 1983 | 91 | 0.010 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 2001 | 42 | 0.010 |
Why?
|
| Physical Chromosome Mapping | 1 | 2001 | 55 | 0.010 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 1 | 2001 | 4 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2001 | 80 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2001 | 110 | 0.010 |
Why?
|
| Regression Analysis | 2 | 1998 | 774 | 0.010 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2001 | 90 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 2 | 1979 | 105 | 0.010 |
Why?
|
| Swine | 1 | 1984 | 1188 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 2001 | 53 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 283 | 0.010 |
Why?
|
| Menstruation | 1 | 1980 | 26 | 0.010 |
Why?
|
| Drug Therapy, Combination | 2 | 1981 | 1164 | 0.010 |
Why?
|
| Rodentia | 1 | 1980 | 50 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 232 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2000 | 157 | 0.010 |
Why?
|
| Cell Count | 1 | 1980 | 220 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2000 | 141 | 0.010 |
Why?
|
| COS Cells | 1 | 2000 | 250 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1999 | 17 | 0.010 |
Why?
|
| CpG Islands | 1 | 2001 | 337 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1983 | 163 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2000 | 147 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1979 | 89 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2003 | 895 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1999 | 137 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2000 | 382 | 0.010 |
Why?
|
| Leucine | 1 | 1980 | 261 | 0.010 |
Why?
|
| Molecular Probe Techniques | 1 | 1999 | 23 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1999 | 82 | 0.010 |
Why?
|
| Lipids | 1 | 1983 | 567 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1999 | 52 | 0.010 |
Why?
|
| Mutagens | 1 | 1999 | 48 | 0.010 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1999 | 39 | 0.010 |
Why?
|
| Mortality | 1 | 1980 | 261 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 3397 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2001 | 801 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 107 | 0.010 |
Why?
|
| Estradiol Congeners | 1 | 1978 | 3 | 0.010 |
Why?
|
| Testosterone Congeners | 1 | 1978 | 15 | 0.010 |
Why?
|
| Receptors, Androgen | 2 | 1979 | 411 | 0.010 |
Why?
|
| Fluoxymesterone | 1 | 1998 | 1 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1999 | 299 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1999 | 436 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 2358 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2000 | 723 | 0.010 |
Why?
|
| Oxygen | 2 | 1973 | 555 | 0.010 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 1998 | 32 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2000 | 357 | 0.010 |
Why?
|
| Neuromuscular Diseases | 1 | 1998 | 48 | 0.010 |
Why?
|
| Breast Diseases | 1 | 1998 | 38 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1998 | 154 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1998 | 62 | 0.010 |
Why?
|
| Actuarial Analysis | 2 | 1992 | 28 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1998 | 81 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 1998 | 97 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1998 | 350 | 0.010 |
Why?
|
| Mitomycin | 1 | 1997 | 48 | 0.010 |
Why?
|
| Temperature | 1 | 1978 | 294 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2000 | 264 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1978 | 429 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1976 | 48 | 0.010 |
Why?
|
| Aging | 1 | 1984 | 1257 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1997 | 350 | 0.010 |
Why?
|
| Pain Measurement | 1 | 1998 | 352 | 0.010 |
Why?
|
| Glucose | 2 | 1983 | 853 | 0.010 |
Why?
|
| Ascites | 1 | 1997 | 99 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 1999 | 588 | 0.010 |
Why?
|
| Registries | 1 | 2003 | 1591 | 0.010 |
Why?
|
| Income | 1 | 1996 | 135 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1995 | 23 | 0.010 |
Why?
|
| Metaphase | 1 | 1995 | 31 | 0.010 |
Why?
|
| Pleural Effusion, Malignant | 1 | 1995 | 13 | 0.010 |
Why?
|
| Heterozygote | 1 | 1998 | 726 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1995 | 36 | 0.010 |
Why?
|
| Educational Status | 1 | 1996 | 281 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 1976 | 123 | 0.010 |
Why?
|
| Buffers | 1 | 1995 | 29 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1996 | 298 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1995 | 101 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 1995 | 25 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1995 | 135 | 0.010 |
Why?
|
| Suppositories | 1 | 1994 | 3 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1998 | 339 | 0.010 |
Why?
|
| GRB7 Adaptor Protein | 1 | 1994 | 2 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 1996 | 291 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1998 | 505 | 0.010 |
Why?
|
| Hemoglobinuria | 1 | 1973 | 2 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 790 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1993 | 73 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 623 | 0.010 |
Why?
|
| Catalase | 1 | 1973 | 63 | 0.010 |
Why?
|
| Nitrites | 1 | 1973 | 48 | 0.010 |
Why?
|
| Diet | 1 | 1979 | 1115 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1995 | 610 | 0.010 |
Why?
|
| Lymphoma, Follicular | 2 | 1983 | 32 | 0.010 |
Why?
|
| Caenorhabditis elegans | 1 | 1994 | 250 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1973 | 194 | 0.010 |
Why?
|
| Sodium | 1 | 1973 | 281 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1994 | 1067 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1995 | 456 | 0.010 |
Why?
|
| Atmospheric Pressure | 1 | 1970 | 5 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2000 | 996 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1992 | 357 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 1970 | 46 | 0.010 |
Why?
|
| Aerospace Medicine | 1 | 1970 | 39 | 0.010 |
Why?
|
| Splenectomy | 1 | 1970 | 62 | 0.010 |
Why?
|
| Spleen | 1 | 1970 | 256 | 0.000 |
Why?
|
| Postoperative Care | 1 | 1992 | 307 | 0.000 |
Why?
|
| Blotting, Northern | 1 | 1989 | 236 | 0.000 |
Why?
|
| Leukocytes | 1 | 1970 | 207 | 0.000 |
Why?
|
| Genes, ras | 1 | 1989 | 99 | 0.000 |
Why?
|
| Ascitic Fluid | 1 | 1988 | 29 | 0.000 |
Why?
|
| Stress, Physiological | 1 | 1970 | 261 | 0.000 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1970 | 331 | 0.000 |
Why?
|
| Surveys and Questionnaires | 1 | 1998 | 4008 | 0.000 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1989 | 194 | 0.000 |
Why?
|
| Pleural Effusion | 1 | 1988 | 107 | 0.000 |
Why?
|
| Alopecia | 1 | 1985 | 42 | 0.000 |
Why?
|
| Vomiting | 1 | 1985 | 104 | 0.000 |
Why?
|
| Autopsy | 1 | 1983 | 116 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1983 | 78 | 0.000 |
Why?
|
| Deoxyglucose | 1 | 1983 | 42 | 0.000 |
Why?
|
| Endocrine Glands | 1 | 1982 | 8 | 0.000 |
Why?
|
| Phospholipids | 1 | 1983 | 102 | 0.000 |
Why?
|
| Methods | 1 | 1982 | 121 | 0.000 |
Why?
|
| Autoradiography | 1 | 1982 | 65 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1983 | 526 | 0.000 |
Why?
|
| Cell Separation | 1 | 1981 | 221 | 0.000 |
Why?
|
| Eggs | 1 | 1979 | 22 | 0.000 |
Why?
|
| Steroids | 1 | 1980 | 172 | 0.000 |
Why?
|
| Milk | 1 | 1979 | 108 | 0.000 |
Why?
|
| Calcium | 1 | 1983 | 1040 | 0.000 |
Why?
|
| Dietary Fats | 1 | 1979 | 274 | 0.000 |
Why?
|
| Acute Disease | 1 | 1980 | 1153 | 0.000 |
Why?
|
| Prolactin | 1 | 1977 | 111 | 0.000 |
Why?
|
| Energy Intake | 1 | 1979 | 501 | 0.000 |
Why?
|
| Androgen Antagonists | 1 | 1977 | 114 | 0.000 |
Why?
|
| Lactation | 1 | 1977 | 197 | 0.000 |
Why?
|
| Androgens | 1 | 1977 | 275 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1983 | 1768 | 0.000 |
Why?
|
| Heart Failure | 1 | 1985 | 2341 | 0.000 |
Why?
|
| Child | 1 | 1983 | 26098 | 0.000 |
Why?
|